Takeda Takes Collaborative, Educational Approach In Thai Dengue Initiative

Ties Up With Kao

As it looks to roll out its new dengue vaccine globally, Takeda will work with Kao’s Thai subsidiary on education and prevention activities in Bangkok, later expanding these to wider areas of Thailand, in the first such local collaboration by the private sector. 

Takeda and Kao will collaborate with Thai Gov't Organizations in combatting dengue
Takeda, Kao link on Thai dengue project as vaccine progresses • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. and chemical/cosmetics group Kao Corporation’s Thai subsidiary, Kao Industrial (Thailand) Co., Ltd., have announced a new collaboration with government organizations in Thailand for the nationwide prevention of dengue that builds on the two Japanese firms' respective products for the mosquito-borne disease.

The two companies signed a memorandum of understanding for Thailand Dengue Prevention and Control on 28 October, under which they...

More from Focus On Asia

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By 

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By 

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Asia Deal Watch: Lupin Picks Sandoz To Market Lucentis Biosimilar In Parts Of EU And Asia

Also deals involving Xspray/Handa, Fosun/Expedition, Kaken/Astria, Orchid/Allecra, Sanofi/Visirna, KKR/Healthcare Royalty Partners, Viridian/Kissei, Sandoz/Evotec, Dx&Vx, Dr. Falk/Allianthera, Madrigal/CSPC and Lilly/LTZ.

More from Scrip

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By 

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By 

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By 

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.